| Similar Articles |
|---|
 |
Financial Planning
February 1, 2007
Elizabeth O'Brien |
Do No Harm Kris Jenner, manager of T. Rowe Price's Health Sciences Fund, has kept his fund healthy through changing economic climates.   |
The Motley Fool
March 22, 2010
Brian Orelli |
Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio. |
Investment Advisor
May 2008
Beth Piskora |
A Healthy Portfolio? Healthcare has traditionally been thought of as a defensive sector, since even when economic conditions get bad, people will still take care of their health. |
The Motley Fool
June 12, 2006
Brian Gorman |
Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
The Motley Fool
February 28, 2008
Brian Lawler |
Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year. |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
The Motley Fool
July 30, 2010
Anand Chokkavelu |
5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better. |
Pharmaceutical Executive
August 1, 2012 |
Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency. |
The Motley Fool
January 26, 2011
Brian Orelli |
Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies. |
The Motley Fool
November 7, 2008
Brian Orelli |
Will Obama Make Your Portfolio Healthy? The changes coming in the health-care industry could be a mixed bag of good and bad for your portfolio. |
The Motley Fool
February 27, 2009
Brian Orelli |
Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas. |
The Motley Fool
January 21, 2009
Brian Orelli |
A Copycat on the Prowl Teva Pharmaceutical announces it is partnering with Lonza to develop generic versions of biologics, called biosimilars, or follow-on biologics. |
The Motley Fool
July 30, 2009
Brian Orelli |
A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money. |
The Motley Fool
December 9, 2009
Brian Orelli |
Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon. |
The Motley Fool
August 1, 2008
Brian Orelli |
Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line. |
The Motley Fool
November 3, 2010
Brian Orelli |
A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it. |
The Motley Fool
March 6, 2009
Brian Orelli |
Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now? |
The Motley Fool
June 30, 2005
Brian Gorman |
The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis. |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
BusinessWeek
July 29, 2009
Arlene Weintraub |
Teva Fights for Biotech Generics Teva's Debra Barrett is lobbying hard to shorten the protection period for biotech drugs and get generic versions to market more quickly |
BusinessWeek
August 26, 2010 |
Pockets of Profit in Health-Care Stocks Kris Jenner of the T. Rowe Price Health Sciences Fund on where to find lucrative product pipelines |
The Motley Fool
June 22, 2006
Stephen D. Simpson |
Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors. |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
Financial Planning
February 1, 2005
Neil A. O'Hara |
The Harvest to Come Pharmaceutical stocks may be down, but they're hardly out. For planners and clients who can tolerate the risk of concentration, a selective allocation to the healthcare industry today may represent the ability to buy growth at a value price. |
The Motley Fool
January 23, 2008
Brian Orelli |
Teva Buys In to Biologics Teva Pharmaceutical announces that it was acquiring privately held CoGenesys, for $400 million in cash. |
BusinessWeek
November 3, 2003
Diane Brady |
Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market. |
Pharmaceutical Executive
October 1, 2006
Joanna Breitstein |
"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival. |
Managed Care
January 2007
John Carroll |
Debate Over Biologics Heats Up in Congress One of the possible issues is 'biosimilars,' agents that would fill the role that generics play in traditional pharmacy coverage. |
Financial Planning
April 1, 2006
Donald Jay Korn |
Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds. |
CFO
June 1, 2010
Alix Stuart |
"This Is the Era of Smarter Medicine." A prescription-drug provider says it can thrive even as it helps drive down health-care costs. An interview with Richard Rubino, CFO, Medco Health Solutions Inc. |
The Motley Fool
July 27, 2004
Brian Gorman |
Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans. |
Pharmaceutical Executive
April 1, 2009
Jill Wechsler |
Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs. |
The Motley Fool
January 31, 2008
Brian Orelli |
Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug. |
The Motley Fool
September 9, 2010
Jim Mueller |
Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker. |
The Motley Fool
February 25, 2008
Brian Orelli |
Look Across the Pond for Biosimilars Teva, ratiopharm, and CT Arzneimittel all get positive recommendations for their new biosimilars, as approvals for generic equivalents to biotech drugs are heating up in Europe. |
The Motley Fool
November 4, 2009
Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool
April 13, 2009
Brian Orelli |
Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion. |
Pharmaceutical Executive
February 1, 2009
Jill Wechsler |
Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths. |
The Motley Fool
December 2, 2009
Brian Orelli |
Tired of Waiting, Teva Advances Teva Pharmaceutical decides it's not worth waiting for the U.S. government to establish a pathway for approval of generic versions of biologic drugs. Instead, it's asking for approval for its copycat of Amgen's Neupogen under the normal branded-drug process. |
The Motley Fool
February 8, 2011
Brian Orelli |
A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers. |
The Motley Fool
December 10, 2008
Brian Orelli |
Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline. |
The Motley Fool
January 27, 2011
Rich Smith |
What's Behind the Run-Up at Rexahn? The pharmaceutical's hot streak could soon burn up all its cash. |
The Motley Fool
April 25, 2011
Sean Williams |
Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
Pharmaceutical Executive
September 1, 2011
Jill B. Conner |
Complex Biologics: The View from Teva Industry and regulators alike must grapple with the sensitivities associated with developing bio-similar drugs. |
The Motley Fool
February 25, 2009
Brian Orelli |
The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers. |
The Motley Fool
April 19, 2011
Bryan White |
Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies. |
The Motley Fool
May 7, 2008
Brian Orelli |
Teva's on a Tear The generic-drug maker can't be stopped. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
